ABSTRACT CATEGORIES

The 2020 abstract categories, along with their related subcategories and subclassifications, are given below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the Annual Meeting 2020. Please note that these abstract categories may or may not be used as Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification.

MCB  Molecular and Cellular Biology, Genetics

MCB01  Cell Growth Signaling Pathways
- Cell signaling
- Cell-cell interactions
- Growth factors
- GTPases, their regulators, and effectors
- Kinases and phosphatases
- Receptors
- Tumor-stromal cell interactions
- Ubiquitin and ubiquitin-like proteins
- Other

MCB02  Cell Death
- Apoptosis
- Autophagy
- Bcl-2 family proteins
- Caspases
- Effectors of apoptosis
- Inhibitor of apoptosis (IAP) family proteins
- Necrosis and necroptosis
- Transcriptional control of apoptosis
- Other

MCB03  Oncogenes and Tumor Suppressor Genes
- Cytoplasmic signal transducers
- Genotype/phenotype correlations
- Nuclear oncoproteins and tumor suppressor genes
- Oncogene growth factors and their receptors
- Tumor suppressor genes
- Other

MCB04  Gene Regulation and Transcription Factors
- Chromatin structure and function
- Gene expression
- Mechanisms of transcription
- Oncogenic transcription factors
- Posttranscriptional and translational control
- Promoters and enhancers of transcription
- Protein-protein interactions in transcription factor function
- Regulation of transcription factor function
- Transcriptional control of cell differentiation
- Other

MCB05  Epigenetics
- Chromatin structure and function
- DNA methylation
- Epigenetic changes as molecular markers of cancer
- Epigenomics
- Gene silencing
- Histone modification
- Other

MCB06  Cell Cycle
- CDKs and CDK inhibitors
- Cell cycle checkpoints
- Control of cell cycle progression
- Mitosis
- Telomeres and telomerase
- Other

MCB07  DNA Damage and Repair
- Chromosomal structural alterations/translocations
- Genomic instability
- Homologous recombination
- Mechanisms of genomic alterations
- Radiation-induced DNA damage
- Other

MCB08  Metabolism and Cancer
- Metabolic pathways
- Metabolomics
- Mitochondrial function
- Signaling pathways that regulate metabolism
- Warburg effect
- Other

MCB09  Genomics
- (See also BSB01: Bioinformatics and Computational Biology)
- Functional genomics
- Genomic profiling of tumors
- High-throughput sequencing
- Large-scale approaches to cancer gene discovery
- Microarrays
- Other

MCB10  microRNAs and Other Noncoding RNAs
- Epigenetic control of miRNA expression
- miRNA regulation of cancer biology
- miRNA profiling in cancer
- miRNA-based diagnostics
- miRNA-based therapeutics
- miRNAs as tumor suppressors/oncogenes
- Noncoding RNAs
- Other

MCB11  Cellular Stress Responses
- Anoikis
- Hypoxia
- Oxidative stress
- Senescence
- Unfolded protein response
- Other

TB  Tumor Biology

TB01  Nonclinical Models of Cancer
- 3-D and tissue recombinant models
- Developmental phenotypes of cancer genes
- Human-in-mouse models of human cancer
- Model organisms in drug discovery
- Mouse models of human cancer
- Noninvasive imaging in animal models
- Organoids
- Patient-derived xenograft models
- Zebrashell models of cancer
- Other
- Animal and cell models of cancer
- Other

TB02  Stem Cell Biology
- Adult stem cells
- Cancer stem cells
- Developmental pathways in cancer
- Embryonic stem cells
- Stem cells and regenerative medicine in oncology
- Stem cell markers
- Other

TB03  Tumor Adhesion
- Cell adhesion and extracellular matrix
- Cell-cell adhesion
- Drug resistance
- Other

TB04  Invasion and Metastasis
- Actin cytoskeleton
- Biomarkers of metastasis
- Epithelial/mesenchymal transition (EMT and MET)
- Expression profiling of tumor progression and metastasis
- Genes that regulate migration and invasion
- Imaging of tumor progression and metastasis
- Invasion and migration
- Metastasis-promoting genes
- Metastasis suppressor genes
- Premetastatic niche
- Therapeutic metastasis prevention
- Other

TB05  Angiogenesis
- Angiogenesis and angiogenesis inhibitors
- Host-tumor interactions
- Molecular mechanisms of angiogenesis
- Novel pro- and antiangiogenic factors
- Tumor microcirculation and the microenvironment
- VEGF/VEGF receptors
- Other

TB06  Tumor Microenvironment
- Chemokines in the microenvironment
- Drug targets in the microenvironment
- Extracellular matrix and integrins
- Gene expression in the microenvironment
- Immune cells in the tumor microenvironment
- Immunity and the microenvironment
- Inflammatory cells as regulators of tumor growth
- Microbiome
- Organ-specific microenvironments
- Proteases and inhibitors in the microenvironment
- Tumor dormancy
- Tumor/stromal interactions
- Tumor-immune system interactions
- Other

TB07  In Vivo Imaging
- (See also CL01: Translational Research – Molecular Biology in the Clinic)
- Advanced nanotechnology and imaging
- Application of imaging technology to the clinic
- Imaging in animal models
- Imaging of molecular and cellular events in the tumor microenvironment
- Imaging of molecular and cellular events in tumors and tumor cells
- Imaging the immune response
- Imaging tumor metabolism
- New targets for imaging
- Other

TB08  Pediatric Cancer - Basic Science
- (See also CL02: Pediatric Cancer - Clinical Investigations; CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer)
- Developmental origins and drivers of pediatric cancer
- Pediatric cancer epigenomics and genomics
- Pediatric cancer models
- Pediatric cancer tumor microenvironment and tumor heterogeneity
- Other
Late-Breaking Abstracts and Clinical Trials Abstract Submission Deadline: January 30, 2020

- Pharmacoprevalence
- Preneoplastic and tumor markers
- Primary and secondary intervention studies
- Risk prediction models for incidence, prognosis, and/or mortality
- Screening and early detection
- Statistical and epidemiological methodology
- Survivorship research
- Other

**PR** Prevention, Early Detection, and Intervention

- Preclinical Prevention, Early Detection, and Intervention
  - Animal models in prevention
  - Biological and biochemical mechanisms in prevention
  - Biomarkers and intervention studies
  - Cellular models
  - Chemoprevention studies
  - Diet, nutrition, and cancer
  - Microbiome and prevention
  - Molecular markers in prevention research
  - Molecular targets for prevention
  - New agent development
  - Screening and early detection
  - Other

- Clinical Prevention, Early Detection, and Intervention
  - Application of molecular pathology in clinical prevention
  - Biomarkers and intervention studies
  - Cancer health disparities research
  - Cancer surveillance and screening studies
  - Chemoprevention clinical trials
  - Genetic markers as surrogate endpoints in prevention trials
  - Genomics and proteomics in cancer risk and response assessment
  - Infections and viral-related cancers
  - Microbiome and prevention
  - Prevention and treatment of premalignant lesions (intraepithelial neoplasia)
  - Prevention of second cancers
  - Recruitment of special populations in clinical prevention trials
  - Screening and early detection
  - Other

- Implementation Science
  - Behavioral science and prevention
  - Cancer communication and decision making
  - Cancer health disparities research
  - Genetic testing and counseling
  - Health policy and outcomes
  - Obesity, diet, physical activity, and energy balance
  - Quality of life/late effects/survivorship
  - Tobacco: Use, effects, prevention, and cessation
  - Other

**BSB** Bioinformatics, Convergence Science, and Systems Biology

- Bioinformatics and Computational Biology
  - Analytic pipeline optimization
  - Application of bioinformatics to cancer biology
  - Database resources
  - Molecular modeling
  - New algorithms
  - New software for data analysis
  - Sequence analysis
  - Statistical methods
  - Other

**CL** Clinical Trials

- Clinical Trials (including Combination and Immunotherapy Trials)
  - All clinical trials should be submitted by the January 30, 2020 clinical trials and late-breaking abstract deadline.

- Phase I Adult Clinical Trials
  - (See also ET05: Pharmacology, Pharmacogenetics, and Pharmacogenomics)

- Phase II Adult Clinical Trials

- Phase III Adult Clinical Trials

- Phase I, II, or III Clinical Trials in Pediatric Cancer
  - (See also CL02: Pediatric Cancer – Clinical Investigations; TB08: Pediatric Cancer – Basic Science)

- Phase I, II, or III Clinical Trials in the Elderly

- Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations

- Clinical Trials in Progress
  - Phase I clinical trials
  - Phase II clinical trials
  - Phase III clinical trials

- Clinical Research
  - [not including clinical trials; see also the Clinical Trials (CT) categories]

**RSP** Regulatory Science and Policy

- Regulatory Science and Policy
  - Biosimilars and generics
  - Clinical trial design and accrual
  - Combination therapies and codevelopment of investigational agents and diagnostics
  - Data science and informatics
  - Novel endpoints and biomarkers
  - Real world evidence and retrospective analyses
  - Tobacco and e-cigarette regulation
  - Other

**SHP** Science and Health Policy

- Science and Health Policy
  - Cancer health disparities
  - Cancer prevention
  - Cancer survivorship
  - Comparative effectiveness research
  - Implementation science
  - Patient advocacy and engagement
  - Value and cost issues in cancer care
  - Other